Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a buddy system ease the burden of a rare lung disease?

NCT ID NCT06811389

Symptom relief Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a 10-week program called RISE-HP for people with hypersensitivity pneumonitis (HP), a lung condition that can cause anxiety, depression, and poor quality of life. Participants work one-on-one with a trained peer coach (someone who also has HP) to learn coping skills and get disease education. The goal is to see if this approach is practical and helps people feel better. The study compares RISE-HP to a general health education program and will enroll 42 adults in the U.S.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral intervention (peer coaching with cognitive behavioral therapy and education)
What this could lead to
If it works, this could provide a new way to help people with hypersensitivity pneumonitis feel better day-to-day and manage their condition more effectively.
What could go wrong
This is a small, early feasibility study (42 people) testing a behavioral program, not a drug. It may not show clear benefits, and results may not apply to everyone with HP.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have documented diagnosis of Hypersensitivity Pneumonitis by treating clinician. * Age 18 or older. * English Speaking. * Willing to work with a peer coach. * Have a working smart phone or tablet. * Have access to the internet. * Reside or live in the United States. * Endorse verbal approval from treating physician to participate in patients' goal movement/physical activity. * Meet one or more of the following criteria: * Baseline score on the PHQ8 of \<20 Exclusion Criteria: * Does not have Hypersensitivity Pneumonitis * Younger than age 18 * Severe cognitive impairment as determined by their treating physician. * Participants with severe depression (PHQ-8 score ≥20) will be ineligible for the study and will be referred to alternative sources of care. * Anyone with documentation in their medical chart of an eating disorder, active substance use disorder, suicidality, homicidality, acute posttraumatic stress disorder, or episodes of mania or psychosis. * Anyone who is determined to be severely ill or moribund by the treating clinician.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypersensitivity pneumonitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypersensitivity pneumonitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypersensitivity pneumonitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Weill Cornell Medicine

    RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.